Avanos Medical (NYSE:AVNS) Sets New 52-Week Low – Should You Sell?

Avanos Medical, Inc. (NYSE:AVNS) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $14.24 and last traded at $14.27, with a volume of 189699 shares changing hands. The stock had previously closed at $14.40.

Analyst Ratings Changes

Separately, StockNews.com raised Avanos Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, March 19th.

Avanos Medical Stock Down 1.7 %

The company’s 50 day moving average is $15.80 and its 200 day moving average is $18.58. The company has a market cap of $651.40 million, a PE ratio of 41.65 and a beta of 1.17. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last issued its earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.40 by $0.03. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The business had revenue of $179.60 million for the quarter, compared to the consensus estimate of $177.23 million. As a group, analysts predict that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Insider Transactions at Avanos Medical

In other news, SVP Kerr Holbrook sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the completion of the sale, the senior vice president now owns 82,047 shares of the company’s stock, valued at approximately $1,251,216.75. This represents a 7.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.90% of the company’s stock.

Institutional Trading of Avanos Medical

Hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Avanos Medical by 10.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 120,269 shares of the company’s stock worth $1,915,000 after purchasing an additional 11,799 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Avanos Medical by 20.6% during the fourth quarter. Two Sigma Investments LP now owns 72,701 shares of the company’s stock valued at $1,157,000 after buying an additional 12,422 shares during the last quarter. State of Wyoming boosted its holdings in shares of Avanos Medical by 132.0% in the 4th quarter. State of Wyoming now owns 5,137 shares of the company’s stock valued at $82,000 after buying an additional 2,923 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Avanos Medical by 44.4% in the 4th quarter. ProShare Advisors LLC now owns 13,693 shares of the company’s stock worth $218,000 after buying an additional 4,210 shares during the last quarter. Finally, Occudo Quantitative Strategies LP purchased a new position in shares of Avanos Medical in the 4th quarter worth approximately $485,000. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.